Louisiana State Employees Retirement System Has $659,000 Position in Azenta, Inc. (NASDAQ:AZTA)

Louisiana State Employees Retirement System lessened its position in Azenta, Inc. (NASDAQ:AZTA) by 11.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,600 shares of the company’s stock after selling 1,700 shares during the period. Louisiana State Employees Retirement System’s holdings in Azenta were worth $659,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its position in shares of Azenta by 16.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,298,856 shares of the company’s stock valued at $62,917,000 after buying an additional 183,040 shares during the last quarter. Net Worth Advisory Group bought a new position in shares of Azenta during the third quarter worth about $205,000. Wesbanco Bank Inc. boosted its holdings in shares of Azenta by 72.2% during the 3rd quarter. Wesbanco Bank Inc. now owns 31,000 shares of the company’s stock worth $1,502,000 after buying an additional 13,000 shares in the last quarter. Procyon Advisors LLC bought a new position in Azenta during the third quarter worth $247,000. Finally, Green Alpha Advisors LLC boosted its position in shares of Azenta by 3.5% during the 3rd quarter. Green Alpha Advisors LLC now owns 10,203 shares of the company’s stock worth $494,000 after purchasing an additional 348 shares in the last quarter. Institutional investors and hedge funds own 99.08% of the company’s stock.

Azenta Trading Up 8.9 %

Shares of AZTA stock opened at $44.90 on Tuesday. The firm has a market capitalization of $2.20 billion, a PE ratio of -15.98 and a beta of 1.48. The firm has a fifty day simple moving average of $46.31 and a two-hundred day simple moving average of $50.92. Azenta, Inc. has a 12 month low of $40.24 and a 12 month high of $69.16.

Azenta (NASDAQ:AZTA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.09. The firm had revenue of $173.00 million for the quarter, compared to the consensus estimate of $166.14 million. Azenta had a negative net margin of 23.66% and a positive return on equity of 0.89%. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.13 EPS. On average, equities analysts predict that Azenta, Inc. will post 0.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Evercore ISI decreased their target price on Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and set a $69.00 price objective on shares of Azenta in a report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $66.40.

Insiders Place Their Bets

In related news, CFO Herman Cueto sold 1,595 shares of the business’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $43.68, for a total value of $69,669.60. Following the transaction, the chief financial officer now directly owns 24,604 shares of the company’s stock, valued at approximately $1,074,702.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.77% of the company’s stock.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.